Standard BioTools (NASDAQ:LAB - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.07), Zacks reports. The firm had revenue of $46.72 million during the quarter, compared to the consensus estimate of $43.03 million. Standard BioTools had a negative return on equity of 27.05% and a negative net margin of 79.92%. Standard BioTools updated its FY 2025 guidance to EPS.
Standard BioTools Stock Performance
Standard BioTools stock traded up $0.02 during trading on Friday, reaching $1.07. 8,064,049 shares of the company's stock were exchanged, compared to its average volume of 2,103,859. The company's 50-day moving average is $1.60 and its two-hundred day moving average is $1.80. Standard BioTools has a 52-week low of $1.00 and a 52-week high of $3.04. The firm has a market cap of $396.46 million, a price-to-earnings ratio of -1.50 and a beta of 1.57.
Analysts Set New Price Targets
Separately, KeyCorp cut Standard BioTools from an "overweight" rating to a "sector weight" rating in a report on Thursday.
Check Out Our Latest Research Report on LAB
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Articles
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
